WITH a claim of 90% efficacy in people over 70 years of age even four years post vaccination, GSK has filed its shingles vaccine Shingrix for US regulatory approval.
Zostavax from rival Merck was recently approved for the National Immunisation Program in Australia from 01 Nov (PD 20 Oct).
The above article was sent to subscribers in Pharmacy Daily's issue from 25 Oct 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 Oct 16
